MGIA
VRTX icon

Moneta Group Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Moneta Group Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$445K Sell
996
-111
-10% -$51.8K ﹤0.01% 537
2025
Q4 		$502K Sell
1,107
-70
-6% -$30.2K ﹤0.01% 500
2025
Q3 		$461K Sell
1,177
-69
-6% -$28.8K ﹤0.01% 518
2025
Q2 		$555K Buy
1,246
+74
+6% +$34.1K 0.01% 415
2025
Q1 		$568K Buy
1,172
+112
+11% +$52.2K 0.01% 390
2024
Q4 		$427K Sell
1,060
-246
-19% -$114K 0.01% 437
2024
Q3 		$607K Buy
1,306
+49
+4% +$23.5K 0.01% 368
2024
Q2 		$589K Sell
1,257
-79
-6% -$34.3K 0.01% 351
2024
Q1 		$558K Buy
1,336
+387
+41% +$164K 0.01% 358
2023
Q4 		$386K Buy
949
+64
+7% +$23.6K 0.01% 382
2023
Q3 		$308K Sell
885
-106
-11% -$37.1K 0.01% 400
2023
Q2 		$349K Buy
991
+168
+20% +$56.6K 0.01% 401
2023
Q1 		$259K Buy
+823
New +$247K 0.01% 450
2018
Q1 		– Sell
-3
Closed – – 724
2017
Q4 		$0 Buy
+3
New +$444 ﹤0.01% 552

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Moneta Group Investment Advisors's VRTX Position: Q1 2026 in Review

Moneta Group Investment Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 10% in Q1 2026, selling an estimated $51.8K and leaving 996 shares worth $445K. The position accounts for ﹤0.01% of the portfolio, ranked #537.

Moneta Group Investment Advisors first reported a position in VRTX in Q4 2017 and has held it in 14 quarters since. The position peaked at $607K in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Moneta Group Investment Advisors held 996 shares of Vertex Pharmaceuticals worth $445K as of Q1 2026.
  • Moneta Group Investment Advisors sold 111 Vertex Pharmaceuticals shares in Q1 2026, an estimated $51.8K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Moneta Group Investment Advisors's portfolio in Q1 2026, its #537 holding.
  • Moneta Group Investment Advisors first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 14 quarters since.
  • Moneta Group Investment Advisors's Vertex Pharmaceuticals position peaked at $607K in Q3 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Moneta Group Investment Advisors's 13F filing for Q1 2026, filed 12 May 2026.